Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Segments
  2. Solutions
  3. Insights
  4. Events
  5. About
  6. Contact Us
MAIN/search
MAIN/Segments
Segments/
Segments
  • Pharmaceutical
  • Consumer Health
  • MedTech
  • Public Health & Government
  • Payer & Provider
Pharmaceutical (Global page)

Bringing data science and human science together to advance human health and support the pharmaceutical industry from clinical trials to commercialization.

Learn More
Consumer Health

Connecting with powerful, evidence-based market insights to drive agile thinking, uncover growth potential, and gain competitive advantage in this fast-moving consumer health market.

LEARN MORE
MedTech

Empowering to orchestrate operations across the entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.

Learn more
Public Health & Government

Working across the health system to address key barriers to deliver high-quality, cost-effective care while improving health outcomes using our data-driven and population-centric solutions.

LEARN MORE
Payer & Provider

Delivering a wide range of consulting and technology solutions to support healthcare stakeholders to drive operational efficiency, enhance quality of patient care, and improve systemic outcomes.

learn more
Healthcare Provider Solutions
MAIN/Solutions
Solutions/
Solutions
  • Research & Development
  • Real World Evidence
  • Information Insights
  • Market Research
  • Strategy Consulting
  • Contract Sales & Medical Solutions
  • Patient Solutions
  • AI, Digital & Technology Solutions
Research & Development (Global page)

Clinical development enabled by Connected Intelligence™ which combines data and analytics with deep therapeutic and operational expertise to improve efficiency, enhance precision, and bring therapies to patients faster.

Learn More
Real World Evidence

Harness the power of real-world data and insights to demonstrate value-driven evidence and outcomes to meet stakeholder needs across the healthcare ecosystem and to propel healthcare forward.

LEARN MORE
Information Insights

Pharmaceutical market data and information assets that provide actionable data points to help organizations make intelligent connections and drive healthcare forward.

LEARN MORE
Market Research

Primary Intelligence integrates purpose-built and syndicated research solutions with our wide range of data assets, research methodologies, advanced analytics, and deep domain expertise, generating quality insights for our clients.

LEARN MORE
Strategy Consulting

Trusted advisor and partner to global healthcare organisations, solving the most significant business challenges through extensive healthcare expertise.

LEARN MORE
Related Solutions
Contract Sales & Medical Solutions (Global page)

Optimize commercial success by leveraging our comprehensive outsourced expertise to accelerate time-to-market.

LEARN MORE
Patient Solutions (Global page)

A single window solution provider to support pharmaco’s design, deploy technology and services that help increase access to medicine and improve treatment adherence.

LEARN MORE
AI, Digital & Technology Solutions

Connected Intelligence™, digital insights, data analytics and advanced technology to power smarter decision-making to enable better patient outcomes and improved business results.

LEARN MORE
MAIN/Insights
Insights/
Our Latest Whitepapers

Get the latest insights on our life sciences, healthcare, and medical technology solutions in Asia Pacific. 

Learn More
Blogs, Case Studies & Podcasts

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

Discover Insights

IQVIA APAC Insight

"A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the Asia Pacific healthcare market.

Read The Latest Issue
MAIN/Events
Events/
Upcoming Events & Webinars

View our upcoming events and webinars.

Explore The Latest
On-Demand Webinars

Visit our library of on-demand webinars.

Discover Insights

Featured Event

"Unlocking the Future of Consumer Health: A Special Focus on Senior Consumers

Learn More
MAIN/About
About/
Newsroom

Read the latest updates and press releases.

Learn More
Career Opportunities

Improving human health requires innovative thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

Search Jobs

APAC FOOTPRINT

"Explore our Asia Pacific locations.

Learn more
MAIN/Contact Us
Contact Us/
Blog
Navigating the Diverse Cell, Tissue, and Gene Therapy Landscape in Japan and Asia Pacific (JAPAC)
Wang Xueying Sherry, Principal, Head of Commercial Regulatory Services
Manfred Seow, Director, APAC Cell and Gene Therapy Centre of Excellence
Kiat Yun Tan, Consultant, Commercial Regulatory Services
Faith Tammy Jiaen Wong, Intern, Commercial Regulatory Services
Aug 23, 2022
  • Locations
  • Asia Pacific
  • Navigating the Diverse Cell, Tissue, and Gene Therapy Landscape in Japan and Asia Pacific (JAPAC)

There has been an increasingly wide interest in the use of cell-based and gene therapy products (CGTPs) for the treatment of diseases and physiological conditions due to their potential to address serious, unmet medical needs. CGTPs encompass a wide range of products – from minimally manipulated skin grafts and blood transfusions to Advanced Therapy Medicinal Products such as cell therapy, gene therapy, tissue engineering products etc. [1]. As most regulatory agencies adopt a risk-based approach, pre-approval is not required for minimally manipulated / homologous products. This article will then focus on the regulations for the approval of non-minimally manipulated and non-homologous use CGTPs.

Figure 1. Types of cell and gene therapies

Need for fit-for-purpose regulations

CGTPs are unique from traditional pharmaceutical products as they involve the introduction of live materials into a patient’s body, which comes with certain risks. For instance, patients who are treated with allogeneic cell therapy or in-vivo gene delivery method encounter a higher risk of immunogenicity [2]. To ensure patients’ safety, regulatory requirements of a minimum safety standard for CGTPs have been imposed. However, due to the high batch-to-batch variability in starting material of autologous cell therapies, there is no one-size-fits-all solution. Greater flexibility will need to be accorded in the regulations and for products to be potentially reviewed on a case-by-case basis [3].

The past five years have seen an exponential increase in the number of approvals for CGTPs, in particular for genetically modified cell therapies such as autologous CAR T-cell therapies. Hence, coming up with fit-for-purpose regulations that can address the unique sensitivities of cell and gene therapy products is of increasing importance. The figure below illustrates the increase in regulatory approvals for the different modes of cell, gene, and RNA therapies across a span of seven years:

Figure 2. Approval of number of cell, gene, and RNA therapies in selected countries / region over 7 years [4, 5, 6, 7]

Differences in regulatory frameworks between selected JAPAC countries

Due to the relative novelty of CGTPs, cell and gene therapy frameworks are still in their nascent stages of development in some countries. The lag in creating a viable regulatory framework has resulted in a divergence in frameworks between countries like the United States (US), Europe (EU) and Singapore that have well-established CGTP frameworks, versus emerging economies like Vietnam and Indonesia that lack one.

Harmonisation of CGTP frameworks between countries with an existing framework is also a challenge as CGTPs are classified differently and are thus subjected to different controls and approval pathways in different countries. Regulatory classification and control-wise, the European Medicines Agency (EMA) for instance, regulates ATMPs instead of CGTPs, and classifies ATMPs into four major groups: gene therapy, somatic cell therapy, tissue-engineered therapy and combined advanced therapy. HSA on the other hand, classifies CGTPs into two risk classes based on the extent of manipulation. All in all, the differences in cell and gene therapy regulatory frameworks across multiple countries can be challenging for pharmaceutical companies who are seeking market access in more than one country in parallel.

Figure 3. CGTP Regulatory Framework in US, EU and selected JAPAC Countries [3, 8]
*US and EU are typically used as reference countries in selected APAC countries

The future of CGTPs for the JAPAC region

With the rapid development of CGTPs, establishing harmonised regulatory frameworks that can address their unique characteristics is important. The existence of cross-country industry/regulators coalitions (e.g. APEC RHSC Advanced Therapies Industry Coalition Coordinators, Standards Coordinating Body and Alliance for Regenerative Medicine) can provide a platform for countries in the Asia-Pacific region to share CGTP-related information and good manufacturing practices with one another, as well as to facilitate the establishment of Mutual Recognition Agreements (MRAs). This bodes well for the harmonisation of CGTP regulations in the JAPAC region.

CGTPs offer hope for the treatment of serious diseases with unmet medical need - expertise is required to navigate the regulatory space to ensure regulatory compliance and access into each market. To find out more about cell-based and gene therapy products across the JAPAC region, please click here.

 

References:

[1]. World Health Organisation (2021). WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products. who-public-consultation_cgtp-white-paper_16_dec_2021.pdf

[2]. US Food and Drug Administration (2020). Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use Guidance for Industry and Food and Drug Administration Staff. www.fda.gov/media/109176/download

[3]. Galli, M.C., and Serabian, M. (2015). Regulatory Aspects of Cell and Gene Therapy Products. Advances in Experimental Medicine and Biology. Volume 871. Regulatory-Aspects-of-Gene-Therapy-and-Cell-Therapy-Products.pdf (royanatmp.com) 

[4]. Research, Center for Biologics Evaluation. Approved Cellular and Gene Therapy Products. FDA, June 2022. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.

[5]. Iglesias-Lopez, Carolina, et al. Current Landscape of Clinical Development and Approval of Advanced Therapies. Molecular Therapy – Methods & Clinical Development, vol. 23, Dec. 2021, pp.606-18. https://doi.org/10.1016/j.omtm.2021.11.003.

[6]. Sakurai, A. (n.d.). Regenerative Medicine and Gene Therapy in Japan. PMDA. 000241234.pdf (pmda.go.jp)

[7]. HSA | Class 2 CTGTP Registration. https://www.hsa.gov.sg/ctgtp/registration

[8]. NPRA. Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia. https://www.npra.gov.my/index.php/en/guideline-bio/1527314-guidance-document-and-guidelines-for-registration-of-cell-and-gene-therapy-products-cgtps-in-malaysia-2.html

Related solutions

Contact Us